Allergen avoidance allows tapering off inhaled corticosteroids (ICS) in house dust mite allergic asthma patients.
ID
Bron
Verkorte titel
Aandoening
(Allergic) asthma.
Ondersteuning
Nederlans Astmafonds 98.55
Astra Zeneca
Boehringer Ingelheim
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Use of inhaled corticosteroids.
Achtergrond van het onderzoek
In this study the hypothesis was tested whether allergen avoidance allows tapering off inhaled corticosteroids (ICS) in house dust mite allergic asthma patients.
Asthma patients between 16 and 60 years using ICS were selected from general practices and the general population. With a RAST allergy for house dust mite and other common allergens was determined.
Patients having an allergy to cats and dogs whilst these animals were present in the house were excluded. Patients were instructed by the GP or a nurse to use a self-management plan to adjust the dose of ICS.
After a baseline period of three months patients received house dust mite impermeable bed covers or placebo covers. Follow-up period was two years. Medication use, symptoms and peakflow were recorded in diaries. Exposure to house dust mite allergens was determined by means of dust samples taken from mattresses, by vacuum cleaning in a standardised way.
Doel van het onderzoek
Allergen avoidance allows tapering off inhaled corticosteroids (ICS) in house dust mite allergic asthma patients.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
All patients have been trained to use a self-management plan to adjust the dose of inhaled corticosteroids to symptoms and peak expiratory flow value.
After a run-in period of 3 months the intervention period with placebo controlled allergen avoidance started.
The participants in the intervention group received house dust miet impermeable covers for mattress, pillow and bedding.
The control group received placebo, house dust mite permeable, covers.
Algemeen / deelnemers
P.O. Box 616
C.P. Schayck, van
Maastricht 6200 MD
The Netherlands
+31 (0)43 3882446
onno.vanschayck@hag.unimaas.nl
Wetenschappers
P.O. Box 616
C.P. Schayck, van
Maastricht 6200 MD
The Netherlands
+31 (0)43 3882446
onno.vanschayck@hag.unimaas.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Age of 16-60 year;
2. Treatment for asthma by the GP;
3. Use of inhaled corticosteroids;
4. Allergy for house dust mite allergens.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Serious diseases other than asthma with;
2. A low survival rate;
3. Other diseases, which influence bronchial symptoms and/ or lung function;
4. Exacerbation within one month before the start of the study;
5. The use of oral steroids or inhaled cromoglycates;
6. Use of house dust mite impermeable mattress/bedding covers;
7. Allergy to cats or dogs while keeping these pets.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL332 |
| NTR-old | NTR370 |
| Ander register | : N/A |
| ISRCTN | ISRCTN32862552 |
Samenvatting resultaten
<br><br>
2. van den Bemt L, van Knapen L, de Vries MP, Jansen M, Cloosterman S, van Schayck CP. Clinical effectiveness of a mite-allergen impermeable bed covering system in asthmatic mite-sensitive patients. J Allergy Clin Immun, 2004, 114 (4): 858-62;<br>
<br><br>
3. de Vries MP, van den Bemt L, van der Mooren FM, Muris JWM, van Schayck CP. The prevalence of house dust mite allergy and the use of HDM impermeable covers in a primary care population of patients with persistent asthma in the Netherlands. Prim Care Respir J, 2005, 14 (4): 210-4;<br>
<br><br>
4. de Vries MP, van den Bemt L, Lince S, Muris JWM, Thoonen BPA, van Schayck CP. Factors associated with asthma control. J Asthma, 2005, in press.